Huntington's Disease Treatment Market Analysis Size Share Growth and Forecast to 2032

Huntington's Disease Treatment Market Analysis

The global Huntington's disease treatment market is projected to grow from $1.26 billion in 2024 to $3.06 billion by 2032, with a CAGR of 11.7%.

Key Market Insights

• North America dominates with 83.33% market share in 2023¹
• Tetrabenazine leads the drug segment due to widespread adoption and generic availability
• Hospital pharmacies are the primary distribution channel due to insurance coverage and specialized care requirements

Recent Developments

• February 2024: Teva Pharmaceutical partnered with Jiangsu Nhwa Pharmaceutical for AUSTEDO distribution in China
• December 2023: uniQure N.V. released 30-month data from Phase I/II trials for AMT-130
• August 2023: FDA approved INGREZZA (valbenazine) for HD-associated chorea

Market Drivers

• Rising disease prevalence: 6.37 per 100,000 people in Europe and 8.87 per 100,000 in North America
• Increasing research initiatives and government support
• Growing awareness and early diagnosis

Market Challenges

• Side effects of long-term drug use
• Strict regulatory requirements
• Limited approved treatment options

Report-

Fortune Business Insights - Huntington's Disease Treatment Market Size, Share [2032]

https://www.fortunebusinessinsights.com/huntington-s-disease-treatment-market-107140